Pfizer Bullish On Danuglipron’s Position In Oral GLP-1 Race
The company believes it still has a good shot at getting an oral GLP-1 to market ahead of many competitors, if not necessarily ahead of Lilly.
The company believes it still has a good shot at getting an oral GLP-1 to market ahead of many competitors, if not necessarily ahead of Lilly.